<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5049">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02147002</url>
  </required_header>
  <id_info>
    <org_study_id>KB305/2012</org_study_id>
    <secondary_id>BS209</secondary_id>
    <nct_id>NCT02147002</nct_id>
  </id_info>
  <brief_title>Omega-3 Acids and Cardio - Vascular Complications in Patients With Chronic Kidney Disease and Hemodialysis</brief_title>
  <acronym>Omega-3 acids</acronym>
  <official_title>Omega 3 Acids and Cardio - Vascular Complications in Patients With Chronic Kidney Disease and Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Collegium Medicum w Bydgoszczy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Collegium Medicum w Bydgoszczy</source>
  <oversight_info>
    <authority>Poland: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The National Register of Nephrology in 2007 shows, similarly to the European data, a
      problem of a high mortality rate among Polish dialysis patients.

      The main reason of death among chronically dialysis patients are cardio - vascular system
      diseases. According to &quot;The Report on the Condition of Renal Replacement Therapy in Poland
      in 2007&quot;, these diseases are the cause of 53% deaths in Poland. The patients with chronic
      kidney disease (PChN) are particularly at risk of cardio - vascular complications. These
      complications occur on average 30 times more often than in the whole population, and among
      young dialysis people, these complications occur 300 times more often. In the development of
      cardio - vascular complications polyunsaturated Omega-3 acids (especially eicosapentaenoic
      acid - EPA and docosahexaenoic acid - DHA) take a special position. The reaction of
      polyunsaturated Omega-3 acids on the cardiovascular system results from the enrichment of
      phospholipids of cell membranes within EPA and DHA. It should be noted that their impact is
      dependent on the type of acid and on the dose. Docosahexaenoic acid reacts with lipids and
      lipoproteins, blood pressure, heart rate, amount of glucose, and eicosapentaenoic acid is
      responsible for antiplatelet effect.

      This project is aiming at defining and elaborating on the connection between Omega-3 acids,
      and cardiovascular complications, their influence on the functioning of the cardiovascular
      system, and moreover, a better understanding of the effects of therapeutic and
      pharmacological therapies in patients at different stages of chronic kidney disease.
      Carrying out this project will be a good start to shape an international project in this
      area.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The survey will cover 90 patients from chronic kidney disease at different stages of the
      disease(I-III) and 30 healthy subjects as a comparison group.

      At the beginning and at the end of the observation period, besides the clinical test, some
      other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory
      blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as:
      lipid profile, uric acid, C reactive protein (CRP), blood urea nitrogen (BUN), creatinine,
      morphology, calcium (Ca),phosphorus (P), Ca x P, ionogram,  xanthine oxidase,  monocyte
      chemoattractant protein (MPC1),Omega-3 acids, resolvin and protectins - the metabolites of
      Omega-3 acids, creatinine excretion, MPC1 excretion  and excretion of uric acid. The
      patients will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where
      1 capsule = 1000 mg) for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>cardiovascular complications</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary measurement before the supplementation and the second measurement after 6 months of supplementation with omega-3 acid.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Cardiovascular Complications</condition>
  <arm_group>
    <arm_group_label>omega 3 acids 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with CKD stage I (GFR 90 and more ml/min/1,73 m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omega 3 acids 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with CKD stage II (GFR 80-89 ml/min/1,73 m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omega 3 acids 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omega 3 acids 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients without diabetes mellitus, hypertensions,CKD with normal level of creatinine in serum</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gold omega 3</intervention_name>
    <description>At the beginning and at the end of the observation period, besides the clinical test, some other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as: lipid profile, uric acid, CRP, BUN, creatinine, morphology, Ca, P, Ca x P, ionogram, xanthine oxidase, MPC1,Omega-3 acids, resolvin and protectins - the metabolites of Omega-3 acids, creatinine excretion, MPC1 excretion and excretion of uric acid.The patients will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where 1 capsule = 1000 mg) for 6 months.</description>
    <arm_group_label>omega 3 acids 1</arm_group_label>
    <arm_group_label>omega 3 acids 2</arm_group_label>
    <arm_group_label>omega 3 acids 3</arm_group_label>
    <arm_group_label>omega 3 acids 4</arm_group_label>
    <other_name>omega 3 acids</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - chronic kidney disease (CKD) stage 1-3

        Exclusion Criteria:

          -  without diabetes

          -  without Immunosuppressive therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacek Manitius, prof.</last_name>
    <role>Study Director</role>
    <affiliation>Collegium  Medicum in Bydgoszcz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agnieszka Pluta, dr</last_name>
    <phone>693716980</phone>
    <phone_ext>0048</phone_ext>
    <email>agnieszkapluta@poczta.onet.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>1Katedra i Klinika Nefrologii, Nadciśnienia Tętniczego i Chorób Wewnętrznych, Bydgoszcz</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka Pluta, dr</last_name>
      <phone>693716980</phone>
      <phone_ext>0048</phone_ext>
      <email>agnieszkapluta@poczta.onet.pl</email>
    </contact>
    <investigator>
      <last_name>Paweł Stróżecki, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>May 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Collegium Medicum w Bydgoszczy</investigator_affiliation>
    <investigator_full_name>Jacek Manitius</investigator_full_name>
    <investigator_title>prof. dr hab. n.med.</investigator_title>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Cardiovascular Complications</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
